PATENT CLAIM ANALYSIS

Application Number: 16011550
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "186100"]

Abstract:
The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

Claim (Index 5):
The lentiviral particle of  claim 3 , wherein the target cell is a CD4+ T cell.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 94.0
- Lexical Diversity: 1.12903
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15668223', '13266236', '14254771', '15849062', '11683962']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7957711475995798
- 35 USC 102 Novelty (BERT): 0.6639268901606604
- Combined Prediction Score: 0.7825867218556879
- Mean Citation Score: 453.18526
- Max Citation Score: 770.7172
- Similarity Product: 611.7573195722342

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test